Andy Fu

OnCusp Therapeutics is a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was founded by a team of accomplished veterans with a proven track record in building a startup biotech to the commercialization stage, leading successful global clinical programs, and creating value in mutually beneficial partnerships. We are committed to accelerating the advancement of globally competitive oncology assets by leveraging our deep translational and clinical development expertise. Co-led the launch of OnCusp Therapeutics, crafting a robust business model and securing $39Mn in seed rounds. Built the Business Development (BD) team and additional support functions from the ground up. Successfully executed 5 deals in 2 years, helping to build up OnCusp’s portfolio including the lead asset, a global second-in-class CDH6 ADC (and potentially best-in-class). As part of the executive team, played a critical role in raising an oversubscribed $100 million Series A, co-led by Novo Holdings, OrbiMed, and F-Prime.

CStone is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a management team with extensive experience in innovative drug development, clinical research, and commercialization. The Company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received eleven NDA approvals for four drugs. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. Supervised a team of 5 and oversaw all Business Development and Corporate strategy activities, including M&A, in-license, out-license, clinical collaborations, and corporate strategy development. Led the EQRx ex-China out-license deal for CStone’s PD-L1 and PD-1, securing an upfront payment of $150Mn and a total deal value of $1.3Bn. Led the LegoChem in-license agreement, obtaining global rights for a global 3rd-in-class ROR1 ADC with an upfront payment of $10Mn and a total deal value of $363.5Mn.

Led a comprehensive strategic collaboration with Pfizer from initial outreach to deal execution, securing an equity investment of $200Mn by Pfizer at a 43.8% premium over the previous day closing price and milestone payments of $280Mn. Led a global clinical collaboration between CStone’s PD-L1 and Bayer’s regorafenib. Led a regional in-license agreement with Numab for a potential BIC tri-specific asset. Led four other undisclosed deals, including three in-licensing and one out-licensing.

Served as project manager for a portfolio in-license deal with Blueprint, obtaining three late-stage precision medicine assets for Greater China with an upfront payment of $40Mn and a total deal value of $386Mn. Contributed significantly to the in-license deal with Agios, securing a commercial-stage FIC IDH1 inhibitor for Greater China with an upfront payment of $12Mn and a total deal value of $442Mn. Served as the project manager for CStone’s Series B financing round, which successfully raised $262Mn.

Formulated multiple strategic plans, including a market positioning strategy for a foreign-owned hospital in Shanghai, a growth blueprint for a multinational drug distributor, and an organizational strategy for a top 10 global pharmaceutical company. Performed rigorous due diligence on multiple public hospitals for China's largest healthcare company, uncovering potential synergies and risks. Led the Asia-Pacific region in a post-merger integration project involving two global diagnostics companies, ensuring seamless integration across five countries.

Co-managed a company of 70 employees with US$30M in revenues, overseeing annual budget approvals, staff performance reviews, and P&L performance optimization. Co-led with the CEO three M&A transactions totaling US$100Mn+ in value

Practiced as a pharmacist at the second busiest store in a district of 26 pharmacies, filling an average of 400 prescriptions daily

President of Consulting Club and Healthcare Club